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Abstract
The incidence of gastric cancer (GC) fell dramatically 
over the last 50 years, but according to IARC-Globocan 
2008, it is the third most frequent cause of cancer-
related deaths with a case fatality GC ratio higher than 
other common malignancies. Surgical resection is the 
primary curative treatment for GC though the overall 
5-year survival rate remains poor (approximately 
20%-25%). To improve the outcome of resectable 
gastric cancer, different treatment strategies have 
been evaluated such as adjuvant or perioperative 
chemotherapy. In resected gastric cancer, the addition 
of radiotherapy to chemotherapy does not appear to 
provide any additional benefit. Moreover, in metastatic 
patients, chemotherapy is the mainstay of palliative 
therapy with a median overall survival of 8-10 mo 
and objective response rates of merely 20%-40%. 
Therefore, the potential for making key beneficial 
progress is to investigate the GC molecular biology 
to realize innovative therapeutic strategies, such as 
specific immunotherapy. In this review, we provide 
a panoramic view of the different immune-based 
strategies used for gastric cancer treatment and 
the results obtained in the most significant clinical 
trials. In detail, firstly we describe the therapeutic 
approaches that utilize the monoclonal antibodies 
while in the second part we analyze the cell-based 
immunotherapies.
Key words: Gastric cancer; Immunotherapy; Monoclonal 
antibodies; T cells; Dendritic cells; NK cells
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Core tip: The overall 5-year survival rate of gastric cancer 
after surgery resection remains poor (approximately 
20%-25%) also adopting different treatment strategies, 
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such as adjuvant chemotherapy, adjuvant chemo-
radiotherapy and perioperative chemotherapy. Several 
data support the idea that anti-gastric cancer (GC) specific 
immunotherapy could be an interesting therapeutic 
strategy. In this review, we provide a panoramic view of 
the various immune-based approaches adopted and the 
results obtained in the most significant clinical trials with 
GC patients.
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INTRODUCTION
The incidence of gastric cancer (GC) fell dramatically 
over the last 50 years, but according to IARC-Globocan 
2008, GC is still the third most frequent cause of 
cancer-related deaths after lung and liver cancer in 
male, and after breast and lung cancer in female[1,2]. 
Interestingly, there is a marked geographical variation 
in GC incidence, with the highest rate in Japan, China 
and Eastern Europe and the lowest in North America, 
India, Philippines and Australia. Histologically, there 
are three subtypes of gastric adenocarcinoma: 
intestinal, diffuse and indeterminate (mixed type). Of 
those, intestinal subtype influences the changes in the 
epidemiological incidence[3]. 
Worldwide, the well known epidemiological ob-
servation in gastric cancer includes: (1) If migrants 
from high risk areas move to low risk areas (China to 
North America), the incidence rate shows a remarkable 
reduction reaching to almost equal rates as in low 
risk countries[4]; and (2) preventable by lifestyle 
modification such as reduced salt intake and increased 
vegetable and fruit consumption, together with 
avoidance of smoking and countermeasures against 
Helicobacter pylori (H. pylori) infection, reduce the risk 
of gastric cancer[5]. 
Case fatality GC ratio is higher than other common 
malignancies, such as colon, breast and prostate 
cancer[6]. Cancer excision is the principal remedy 
for GC though the 5-year survival rate is not high 
(approximately 20%-25%). To improve the outcome of 
resectable gastric cancer, different treatment strategies 
have been evaluated such as adjuvant chemotherapy, 
adjuvant chemo-radiotherapy, and perioperative 
chemotherapy.
The US Intergroup 0116 trial reported the benefit of 
postoperative-chemo-radiotherapy using 5-fluorouracil 
(5-FU)/leucovorin in a US population. In this study, 
only 10 % of patients received D2 resection. In Korean 
patients after D2 resection, the ARTIST trial failed to 
show any benefit from adding radiotherapy to adjuvant 
chemotherapy in terms of 3-year disease-free survival. 
The MAGIC trial compared perioperative chemotherapy 
with surgery alone and reported a prolonged 5-year 
overall survival in the perioperative chemotherapy arm. 
In resectable gastric cancer, the benefit of adjuvant 
chemotherapy compared with surgery alone has been 
clearly demonstrated. After D2 dissection, S-1 adjuvant 
chemotherapy improved the overall survival (ACTS-
GC trial) and capecitabine/oxaliplatin combination 
chemotherapy improved 3-year disease-free survival 
(CLASSIC trial). To date, for resectable gastric cancer, 
the use of chemotherapy in addition to surgery has 
proved to be beneficial in decreasing the rate of 
recurrence and improving overall survival. The optimal 
sequence of chemotherapy and surgery, as well as the 
development of new optimal chemotherapeutic agents, 
are future goals for research. In D2-resected gastric 
cancer, the addition of radiotherapy to chemotherapy 
does not appear to provide any additional benefit[7-11].
First-line chemotherapy raises the overall survival 
(OS) of patients with advanced GC and the association 
of two drugs (generally fluorouracil and cisplatin) 
was more effective than monotherapy[12]. Moreover, 
the addition of a third drug (e.g., anthracycline or 
docetaxel) to a platinum-fluoropyrimidine association 
further increases the OS[13,14]. Lastly, both capecitabine 
and oxaliplatin had similar results to fluorouracil and 
cisplatin, respectively, about the OS and progression-
free survival (PFS)[14,15].
In metastatic GC patients, chemotherapy is the 
column of palliative treatments with a median OS 
of 8-10 mo and objective response rates (ORRs) of 
merely 20%-40%[16].
Therefore, the potential for making key beneficial 
progress is to investigate the molecular biology of 
tumors to realize innovative therapeutic strategies, 
such as specific immunotherapy[17,18].
The behavior of immune response is centered 
on a task partition involving the innate (especially 
macrophages, dendritic and NK cells) and specific 
immune response (T and B lymphocytes), that 
often cooperate to obtain an efficacious anti-cancer 
response. Up to now, various strategies (vaccines, T 
cells infusion or cytokines) have been proved to be able 
to stimulate the immune system, exploiting essentially 
two principal mechanisms: (1) strengthening the anti-
tumor response (by raising the amount of effective 
cells and/or cytokines/chemokines); or (2) increasing 
the immunogenicity and/or susceptibility of cancer 
cells.
However, the neoplastic cells are able to develop 
various strategies to evade immune surveillance: 
decrease of tumor antigen or MHC expression, 
modulation of Fas-L, secretion of inhibitory cytokines 
[interleukin (IL)-10 and/or TGF-β] and generation of 
regulatory cells such as Tregs (regulatory cells) and 
myeloid-derived suppressor cells (MDSC)[19,20].
In other words, the prerequisite for an effective 
anti-tumor immune-based treatment is the stimulation 
of a successful cancer-specific immune response, able 
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to crack the immunological tolerance of tumor cells. 
The aim of this review is to provide a panoramic view 
of the different immune-based strategies used for 
GC management (Figure 1) and discuss the data of 
the most significant clinical trials. In detail, firstly we 
describe the therapeutic approaches that utilize the 
monoclonal antibodies while in the second part we 
analyze the cell-based anti-GC treatments.
MONOCLONAL ANTIBODIES DIRECT TO 
MOLECULAR AND CELLULAR GASTRIC 
CANCER TARGETS
The typical paradigm of drug development, especially 
for targeted therapies, has primarily been in the 
metastatic setting, followed by introduction into 
chemoradiation, and finally, subsequent evaluation in a 
randomized trial.
In this paragraph, we will focus on three of the 
most widely studied therapies with monoclonal 
antibodies (moAb) in gastric cancer: anti-epidermal 
growth factor receptor (anti-EGFR), anti-HER2 and 
anti-vascular endothelial growth factor (anti-VEGF); 
as they have been evaluated by this paradigm. The 
second part will focus on pathways and drug targets 
currently under evaluation for gastric cancer.
Anti-epidermal growth factor receptor (cetuximab/
panitumumab/matuzumab)
EGFR (ERBB1) is an element of the ERBB trans-
membrane growth factor receptor family, that 
promotes and modulates, via a receptor-associated 
tyrosine kinase (TK), various cell processes such as 
apoptosis or proliferation[21].
The EGFR hyperexpression shows a relationship 
with augmented invasion and more unfavorable 
prognosis of patients with esophago-gastric cancers 
(EGC)[22-25]. In addition, the anti-EGFR MoAb therapy 
is ineffective in colorectal cancer (CRC) patients that 
have K-ras mutations[26-28].
Lately, Janmaat et al[29] showed mutated K-ras in 
8.7% patients with EGC; but the prognostic role of 
K-ras status in the anti-EGFR therapy is practically 
indefinite.
Existing anti-EGFR treatments in EGC patients 
consist of oral TK inhibitors (TKIs; erlotinib, gefitinib) 
and moAb (cetuximab, panitumimab and matuzumab). 
Cetuximab obstructs the lignad junction with the 
EGFR[30], promotes EGFR internalization[31] and also, 
can start the immune-mediated cytotoxicity[32,33].
Due to the better ORR and time-to-progression (TTP) 
for the cetuximab/irinotecan association compared with 
the irinotecan monotherapy[34] , the FDA (Food and 
Drug Administration) has been approved the cetuximab 
use in irinotecan-refractory CRC.
In addition, the FDA has been authorized the 
Panitumumab therapy of chemo-refractory EGFR-positive 
CRC, because a recent study showed an amelioration in 
ORR and PFS over best current treatment[35]. Besides, 
a phase Ⅰ study reported a stable disease (SD), for 
7 mo, in one refractory EGC patient, treated with 
panitumumab[36].
Lastly, a recent study showed that one patient, with 
esophageal cancer (EC), cured with Matuzumab (the 
last anti-EGFR moAb) had a durable six-month PR[37]. 
Also, the combination of matuzumab with the ECX 
regimen (epirubicin/cisplatin/capecitabine) registered 
encouraging results as first-line therapy in patients 
with EGFR+ gastric cancer. The ORR in 20 evaluable 
patients was 65% with a median TTP of 5.2 mo[38].
Metastatic results: Numerous phase Ⅱ studies 
have been performed with cetuximab in combination 
with chemotherapy in advanced EGC. One of the first 
trials[39] evaluated cetuximab with FOLFIRI in thirty-
eight patients with untreated advanced gastric or 
GE junction adenocarcinoma. Cetuximab was given 
with an initial loading dose of 400 mg/m2 followed 
by weekly doses of 250 mg/m2. The overall response 
rate was 44.1%, with a median survival of 16 mo. In 
another randomized phase Ⅱ study, cetuximab was 
added to 3 chemotherapy regimens: ECF (epirubicin, 
cisplatin, 5-FU), IC (irinotecan/cisplatin), and FOLFOX[40]. 
The response rates were 58%, 38%, and 51% in the 3 
arms, respectively.
The role of anti-EGFR therapy in advanced EGC was 
tested in a phase Ⅲ study evaluating the efficacy of 
panitumumab with combination chemotherapy in the 
REAL 3 study[41]. Patients with inoperable/metastatic 
esophageal, gastric, or GE junction cancer were 
randomized to receive EOC (epirubicin, oxaliplatin, 
capecitabine) with or without panitumumab. An 
early planned interim analysis showed that the 
panitumumab arm was statistically inferior after 553 
(76%) patients were enrolled. Median survival was 
11.3 mo in the chemotherapy-alone arm vs 8.8 mo for 
chemotherapy plus panitumumab [hazard ratio (HR) 
= 1.37, P = 0.013). Although patients with rash in 
the panitumumab arm did better than those without 
rash, the subgroup of patients with rash still had a 
numerically worse median survival than the entire 
chemotherapy-alone group.
Chemoradiation results: Chemoradiation with 
cetuximab has been extensively studied in the phase 
Ⅱ setting. One clinical study evaluated 60 patients 
treated with cetuximab, paclitaxel, and cisplatin in 
combination with radiation therapy. A pathologic 
complete response rate of 27% was seen with this 
regimen[42]. In the Swiss Group for Clinical Cancer 
Research phase Ⅰb/Ⅱ trial (SAKK 75/06), 28 patients 
with adenocarcinoma or squamous cell carcinoma 
were treated with induction cisplatin, docetaxel, and 
cetuximab followed by radiation therapy to 45 Gy along 
with concurrent cisplatin and cetuximab. A pathologic 
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complete response (pCR) rate of 32% was seen with 
this regimen. Neither of these studies demonstrated 
excess risk with the addition of cetuximab[43].
In contrast, ECOG 2205 evaluated a neoadjuvant 
regimen of cetuximab in combination with infusional 
5-FU, oxaliplatin, and radiation therapy. The study 
was closed after an excessive number of early 
deaths. Four of 18 patients died postoperatively of 
the acute respiratory death syndrome (ARDS) despite 
compliance with strict radiation lung dosimetry 
guidelines. This high rate of ARDS, not seen in other 
studies of 5-FU with oxaliplatin and radiation, raised 
the possibility that cetuximab may have added to the 
risk of postoperative pulmonary complications[44].
Evolution of chemoradiation: Radiation Therapy 
Oncology Group (RTOG) 0436 is a randomized phase 
Ⅲ trial of cisplatin, paclitaxel, and radiation therapy 
to 50.4 Gy with or without cetuximab in inoperable 
esophageal cancer. In the spring of 2012, the study 
underwent a planned interim analysis to document 
superiority of the cetuximab arm as measured by 
clinical complete response rate. The study failed to 
meet this end point and closed to further patient 
enrollment.
The SCOPE1 study from the United Kingdom is 
a similarly designed 2-arm randomized phase Ⅱ
/Ⅲ study comparing cisplatin/capecitabine/radiation 
with or without cetuximab[45]. This study will also 
undergo a planned analysis after the phase Ⅱ portion 
to document a freedom from treatment failure rate 
exceeding 75% at 24 wk in the cetuximab containing 
arm.
Given the negative results of the REAL 3 trial, and 
RTOG 0436 closing enrollment to adenocarcinoma due 
to a lack of efficacy with cetuximab, it is unlikely that 
anti-EGFR strategies will be further developed in the 
United States in unselected patients.
Anti-HER2/ERBB2 (trastuzumab)
HER-2/neu (ERBB2) is part of the ERBB TK receptor 
family. The ligand of these receptors leads to homo/ 
hetero-dimerization of the receptors and with their 
formation displaying a distinct hierarchy. In this 
system, HER-2/neu has a key role because each 
receptor with a specific ligand promotes the association 
with Her-2/neu. This predilection is more influenced 
by Her-2/neu hyperexpression, as seen in numerous 
types of human tumor cells[46].
About EGCs, HER-2/New hyperexpression has 
been shown in esophageal cancer and GE junction 
carcinoma[47,48]. HER-2/neu hyperexpression has been 
connected with increased invasion and poor response 
to neo-adjuvant chemotherapy[49] or overall reduced 
survival[50].
The anti-HER2/neu moAb treatment that has been 
tested in EGC patients is Trastuzumab, that exercises 
its role by different ways: blocking HER-2 receptor 
dimerization, favoring the receptor demolition and 
promoting the cytotoxicity[51]. Currently, it has been 
used in association with chemotherapy for HER-2/neu+ 
and node+ breast cancer[52-56].
Metastatic results: The proof of the therapeutic 
benefit of HER2-directed therapy in gastric and GE 
cancer comes from the trastuzumab for gastric cancer 
trial, a large randomized trial of trastuzumab added 
to standard chemotherapy in HER2+ advanced gastric 
cancer[57]. In this study, patients with HER2+ gastric or 
GE cancer were randomized to either trastuzumab and 
chemotherapy or chemotherapy alone.
Chemotherapy consisted of (5-FU or capecitabine 
in combination with cisplatin given every 3 wk for 
6 cycles. Trastuzumab was continued until disease 
progression. HER2 positivity was defined as 3+ staining 
by immunohistochemistry (IHC). Tumors with IHC 
2+ staining had to be confirmed by the evidence of 
amplification by fluorescence in situ hybridization.
Tumors from 3807 patients were centrally tested 
for HER2 status, of which 22.1% were HER2+. These 
594 patients were randomized to 1 of the 2 treatment 
groups, with well-balanced clinical characteristics. A 
planned interim analysis was performed after 75% of 
the events had occurred, and the independent data 
monitoring committee recommended release of the 
data because the prespecified boundary had been 
exceeded, with a median follow-up of 17.1 mo. Median 
survival was improved with the addition of trastuzumab 
to chemotherapy from 11.1 to 13.5 mo (P = 0.0048; 
HR = 0.74; 95%CI: 0.60-0.91). The overall response 
rate was also improved from 34.5% to 47.3% with the 
addition of trastuzumab (P = 0.0017). The toxicity was 
similar in both arms.
Specifically, there was no difference in congestive 
heart failure. Asymptomatic decreases in left 
ventricular ejection fraction were similar in both arms 
(4.6% with trastuzumab, 1.1% without). Based on 
this study, trastuzumab was approved in the setting of 
HER2+ advanced gastric and GE cancer.
Chemoradiation results: Recently it has been 
performed a pilot study of trastuzumab added to 
chemoradiation in patients with locally advanced 
esophageal carcinoma[58].
Patients were required to have HER2 positivity 
(HER2 2+/3+ expression). Chemoradiation was 
delivered with a dose of 50.4 Gy along with concurrent 
weekly cisplatin (25 mg/m2) and paclitaxel (50 mg/
m2). In cohort 1, 3 patients received a 2-mg/kg bolus 
dose in week 1 followed by a weekly dose of 1 mg/kg. 
In cohort 2, 3 patients received a 3-mg/kg bolus dose 
in week 1 followed by a weekly dose of 1.5 mg/kg. In 
the third cohort, 13 patients received a 4-mg/kg bolus 
dose in week 1 followed by a weekly dose of 2 mg/kg. 
Maintenance trastuzumab was given for 1 year at a 
dose of 6 mg/kg every 3 wk. Despite the advanced 
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disease in many patients, such as celiac adenopathy 
(37%) or retroperitoneal (37%), a striking 3-year 
overall survival of 47% was observed, although a lot 
of patients did not undergo surgery owing to extensive 
adenopathy or medical morbidities. Additionally, there 
were no observed increases in adverse events from the 
addition of concurrent or maintenance trastuzumab. 
Because surgery was not required, there was no 
meaningful pCR data.
Trastuzumab emtansine, or T-DM1, is an antibody- 
drug conjugate linking trastuzumab to a highly potent 
anti-microtubule agent. Preclinical data on human GC 
cells and xenografted tumors suggested that T-DM1 is 
more effective than trastuzumab. Recently, a phase Ⅲ 
study evaluating T-DM1 vs lapatinib and capecitabine 
in HER2+ trastuzumab-refractory breast cancer 
demonstrated an improvement in median survival 
favoring T-DM1 (not reached vs 23.3 mo; HR = 0.621; 
95%CI: 0.475-0.813; P = 0.0005)[59]. Additionally, 
T-DM1 had a higher response rate (43.6% vs 30.8%) 
and duration of response (12.6 mo vs 6.5 mo). 
Furthermore, T-DM1 showed antitumor effects even in 
xenografted tumors that had developed resistance to 
trastuzumab. Based on this evidence, an international 
phase Ⅱ/Ⅲ trial in second-line advanced EGC will open 
randomizing between T-DM1 vs a taxane (weekly 
paclitaxel or q3w docetaxel).
Evolution of chemoradiation: Based on the 
positive results observed in the metastatic setting 
with the addition of trastuzumab as well as the 
encouraging safety and efficacy data from the Brown 
group, the RTOG has initiated a randomized trial, 
RTOG 1010, studying the addition of trastuzumab to 
chemoradiation. In this study, patients with operable 
locally advanced adenocarcinoma of the esophagus 
and GE junction are centrally screened for HER2 
positivity. If the tumor is found to be HER2+, patients 
are randomized to concurrent and maintenance 
trastuzumab in addition to chemoradiation. Chemo-
radiation consists of a dose of 50.4 Gy along with 
weekly carboplatin (AUC 2) and paclitaxel (50 mg/m2). 
The results of this ongoing trial will inform the future 
use of trastuzumab in localized HER2-overexpressing 
esophageal and GE junction cancer[60].
Anti-vascular endothelial growth factor (bevacizumab)
The action of most powerful angiogenic factor, VEGF, 
is started by linking to various high-affinity trans-
membrane receptors, most remarkably VEGFR types 1 
and 2[61].
VEGF is over-expressed in different cancers[62] 
and besides, in esophageal and gastric cancer the 
hyperexpression correlates with cancer stage, bad 
prognosis and reduced survival[63-70]. Also, the moAb 
bevacizumab is an anti-VEGF monoclonal antibody, 
that associated with the chemotherapy increases the 
ORR and TTP in patients with CRC[71] NSCLC[72] and 
breast cancer[73]. It seems that bevacizumab have a 
double anti-cancer effect: as anti-angiogenic factor and 
also increasing chemotherapy drug delivery, favoring 
the decrease of interstitial fluid pressures[74,75].
Metastatic results: Multiple phase Ⅱ studies 
evaluated bevacizumab in combination with a variety 
of chemotherapy regimens in esophagogastric cancer. 
In a phase Ⅱ study[76], the addition of bevacizumab 
to cisplatin and irinotecan showed a response rate of 
65% and a median survival of 12.3 mo. In another 
phase Ⅱ study, Shah et al[77] evaluated bevacizumab 
in combination with docetaxel, cisplatin, and 5-FU. 
This regimen yielded a response rate of 67% and 
an impressive median survival of 16.8 mo. Similarly, 
a high response rate of 68% was observed when 
bevacizumab was combined with docetaxel, cisplatin, 
and irinotecan[78].
With these higher obtained response rates, a 
randomized phase Ⅲ trial was performed evaluating 
the efficacy and safety of bevacizumab in combination 
with chemotherapy. The Avastin in Gastric Cancer 
(AVAGAST) trial randomized patients with inoperable 
locally advanced or metastatic gastric or GE 
junction adenocarcinoma with no previous therapy 
to bevacizumab or placebo in combination with 
capecitabine (or 5-FU) and cisplatin. 774 patients were 
randomized, with 95% of patients having metastatic 
disease[79]. The median survival was 10.1 mo for 
chemotherapy alone vs 12.1 mo for chemotherapy plus 
bevacizumab (HR = 0.87; P = 0.1002). Although this 
result did not reach statistical significance, there was an 
improvement in progression-free survival from 5.3 to 6.7 
mo (HR = 0.80; P = 0.0037), and the overall response 
rate increased from 29.5% to 38% (P = 0.0121). 
However, despite this negative trial, some of the 
trends in the secondary endpoints have led to further 
evaluation of bevacizumab in the metastatic setting.
Chemoradiation results: An interesting study[80] 
demonstrated that bevacizumab could change tumor 
physiology of rectal cancer and theoretically potentiate 
the effects of radiation therapy. In localized esophageal 
cancer, a similar approach was used in a phase Ⅱ trial 
evaluating bevacizumab with erlotinib in a neoadjuvant 
chemoradiation study[81]. Patients with stage Ⅰ-Ⅲ 
esophageal or GE junction cancer were enrolled. Ninety-
five percent of patients had adenocarcinoma, and 93% 
of patients had stage Ⅱ or Ⅲ disease. Bevacizumab 
was added to a regimen consisting of carboplatin (AUC 
5, days 1 and 22), paclitaxel (200 mg/m2, days 1 and 
22), and continuous infusion of 5-FU (225 mg/m2 per 
day, from day 1 to 35) in combination with radiation 
therapy to 45 Gy. Of sixty patients enrolled, a pathologic 
complete response rate of 30% was observed.
Another phase Ⅱ study, reported results of pre-
operative chemoradiation with cisplatin, irinotecan, and 
bevacizumab. Patients with Siewert Ⅰ/Ⅱ adenocarcinoma 
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of the esophagus received induction chemotherapy with 
cisplatin, irinotecan, and bevacizumab. This was followed 
by concurrent chemotherapy with cisplatin, irinotecan, 
and bevacizumab in combination with radiation therapy to 
50.4 Gy. Surgery was followed by adjuvant bevacizumab. 
A pathologic complete response was seen in 4 of 33 
patients (12%). Progression-free survival and overall 
survival were 14 and 30 mo, respectively[82].
Evolution of chemoradiation: The negative primary 
result of the AVAGAST study has mitigated some of 
the enthusiasm for bevacizumab in the context of 
chemoradiation for esophageal cancer. Given the lack 
of improvement in the pathologic complete response 
rate in the phase Ⅱ study discussed earlier in the 
text compared with historical control groups, further 
development of bevacizumab with chemoradiation for 
esophageal cancer is currently not being pursued in a 
phase Ⅲ study[60].
Anti-hepatocyte growth factor/mesenchymal-epithelial 
transition factor (rilotumumab)
The cell surface receptor c-MET [mesenchymal-epithelial 
transition factor (MET)] and its ligand hepatocyte 
growth factor (HGF) are potential therapeutic targets 
in esophagogastric cancer. Physiological MET tyrosine 
kinase activation is mediated by binding of HGF, leading 
to signal transduction down multiple downstream 
pathways, including those involving Ras, PI3K, mTOR, 
STAT3, and NF-κB[83,84]. Additionally, the HGF/MET 
axis can stimulate tumor endothelial cells, thereby 
altering the tumor microenvironment and promoting 
angiogenesis[85,86]. Physiological MET signaling can be 
altered by ligand/receptor overexpression or gene 
amplification as well as MET gene mutations[85]. 
Specifically, MET gene amplification is a driver in some 
esophagogastric cancers[87-90].
Additionally, MET gene mutations have been 
documented in hereditary and sporadic renal carcinoma, 
esophagogastric cancer, hepatocellular cancer, head and 
neck cancer, ovarian carcinoma, small-cell lung cancer, 
and glioma[85,91,92]. Strategies to inhibit the HGF/MET 
axis include blocking both the ligand and the receptor.
Rilotumumab is a human moAb to HGF. In a 
randomized phase Ⅱ study, patients with newly 
diagnosed GC were randomized to receive 1 of 2 
doses of rilotumumab (15 mg/kg or 7.5 mg/kg) in 
combination with ECX (epirubicin, cisplatin, capecitabine) 
chemotherapy or chemotherapy alone[93]. Tumors that 
were IHC+ in > 50% of cells were defined as MET high. 
In the MET-high subgroup, representing approximately 
half of the patients, the 2 rilotumumab arms had a 
median survival superior in the chemotherapy-alone 
arm (11.1 mo vs 5.7 mo; HR = 0.29; 95%CI: 0.11-0.76; 
P = 0.012). In contrast, the MET-low patients in the 
2 rilotumumab-containing arms had a trend toward 
a worse survival than the MET-low patients in the 
chemotherapy-alone arm (HR = 1.84; 95%CI: 
0.78-4.34). In the chemotherapy- alone arm, patients 
with MET-high tumors had a worse overall survival 
(HR = 3.22; 95%CI: 1.08-9.63) than those with MET-
low tumors. This study suggested that expression, 
as opposed to amplification, may be a reasonable 
biomarker. In this study, MET expression was both 
predictive (good) for anti-HGF antibody therapy and 
prognostic (poor). Based on these data, a phase Ⅲ 
study has been planned in the first-line setting for EGC 
patients with MET-high tumors.
CELL-BASED IMMUNOTHERAPY 
APPROACHES
Therapies with T cell
The central anti-cancer role of T cells has been 
highlighted by the documented cancer incidence in 
immunodeficient disorders[94] and by evidence that the 
intra-tumoral T cell infiltration is associated with better 
patient survival[95].
Currently, there isn’t FDA-approved adoptive 
T-cell therapy, but the growing new acquisitions on 
the cancer nature and lymphocyte role do hope that, 
shortly, the adoptive T-cell therapy can become a 
clinical cancer practice. Topical information obtained 
from adoptive transfer in lymphodepleted hosts[96], the 
immunosuppressive capacity of Tregs[97] and the utilize 
of better culture systems[98] have not yet been tested 
in clinical studies.
Essentially exist two different therapeutic protocols 
of T cell-based anti-cancer treatment: (1) cytotoxic T 
lymphocytes (CTL); (2) tumor infiltrating lymphocytes 
(TIL) (Figure 1).
Cytotoxic T lymphocytes: Improved CTL cell culture 
technology has permitted the first clinical tests for 
adoptive transfer of CTLs and this technique[99,100] 
seems to result in substantial activity in melanoma 
patients: 40% of patients showed an anti-tumor 
immune responses[101]. Similar results were obtained 
by Yee et al[102] in an independent trial in which 
engraftment of the CTLs was detectable up to two 
weeks after T-cell transfer in all patients.
Survivin has been demonstrated to be an excellent 
target for immunotherapy in various cancer types and 
recent data suggest a role also in gastric cancer[103]. 
In this study, elevated efficiency was obtained upon 
inducing survivin-derived peptide-specific CTL from 
mononuclear cells isolated from blood of healthy 
donors. The induced CTLs showed specific lysis against 
tumor cells in vitro, and vs primary cell cultures 
isolated from GC patients. These data suggest that 
survivin epitope peptide could be a promising vaccine 
candidate for GC immunotherapy.
Instead, another recent study[104] examined the 
possibility of using cancer-specific immunotherapy 
based upon mitotic centromere-associated kinesin 
(MCAK), a new cancer antigen. To evaluate the 
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feasibility of developing cancer immunotherapy 
using MCAK peptides, Kawamoto et al[104] studied 
HLA-A10201 and 12402 as targets for CTLs.
The CTLs killed HLA-A-10201/12402 colon and 
gastric cancer MCAK+ cells, as well as the peptide-
pulsed target cells, in an HLA-l restricted manner. 
These results prospect the opportunity of designing 
peptide-based immunotherapeutic treatments for 
patients with MCAK+ gastric cancer.
Of late, Kim et al[105] demonstrated the anti-
gastric cancer power of cytokine-induced killer (CIK) 
cells (essentially T CD80+ cells), that were isolated 
from the human peripheral blood mononuclear cells 
(PBMC), cultured in medium with IL-2 and anti-CD3 
antibody. The CIK cells were able to destroy, in vitro, 
the MKN74 cells (a human gastric cancer cell line) and 
to inhibit the MKN74 tumor growth in nude mouse 
model. These results suggest the potential use of 
CIK cells as adoptive GC immunotherapy patients, as 
described in different studies[106,107]. In fact, the CTLs 
from GC patients are capable to attack the autologous 
cancer cells, recognizing specific tumor-associated 
antigens[107,108], such as MG7-antigen, that shows a 
big potential for starting immune responses to gastric 
cancer[109,110]. In addition, the use of HLA-A-restricted 
allogeneic GC cells to stimulate tumor-specific CTLs 
could be a different immunotherapeutic approach for 
GC patients[111]. 
Of note, different studies suggest that the 
association of CIK cells with chemotherapy can be 
functional in advanced GC patients[112,113]. In fact, the 
patients cured with the combined therapy showed 
a significant decrease of serum levels of the cancer 
markers and a marked improvement of life quality, in 
comparison to patients treated only with chemotherapy. 
In summary, preclinical/clinical evidence supports 
the idea that CIK cell immunotherapy can be a 
successful anti-GC treatment, but it is still unclear 
what is the injection via which guarantees the best 
distribution of effector cells.
In a mouse model of gastric cancer Du et al[114] 
observed the distribution of CIK cells injected by three 
different via of infusion: peritumoral (pt), intravenous 
(iv) and intraperitoneal (ip).
They demonstrated that the pt injection produced 
a considerable tumor infiltration of CIK cells for 48 h 
and induced the most tumor inhibition in comparison 
to the ip or iv infusion, that caused a very small 
CIK intratumoral accumulation and a short in vivo 
inhibition of tumor growth only following injection. In 
conclusion, the pt injection of CIK can be an effective 
and minimally invasive approach of adoptive cellular 
immunotherapy for GC patients.
Adoptive transfer therapy with TILs: The use of 
TILs as adoptive transfer therapy is a “not immediate” 
therapeutic approach because it requires about six 
weeks before the T cells would be ready for infusion. 
In fact, the protocol necessitates firstly the T cell 
isolation from neoplastic tissue, after the in vitro 
Figure 1  Different immunotherapy approaches. The figure illustrates the two different vaccination approaches (using DNA or peptides) and the cellular and 
molecular elements used in anti-cancer immunotherapy. The adopted specific immune mechanisms are monoclonal antibodies and T cells: CD8+ (CTL) or CD4+ (T 
helper). About innate immune mechanisms, cytokines, dendritic cells (DCs) and natural killer cells (NKs) represent the most exploited components.
Adaptive immune mechanisms
CD8+ T cells Antibodies CD4
+ T cells
ImmunotherapyDNA vaccines Peptide vaccines
Innate immune mechanisms
CytokinesDC NK cells
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expansion and finally the selection of tumor-specific 
T cells. In addition, only 30%-40% of the biopsies 
yield acceptable T-cell populations and the whole 
process[115]. So, the adoptive transfer of TILs has been 
promising in preclinical models[116] but not in clinical 
trials[117,118], except for the melanoma patients for 
easy surgical availability of the tumor tissue. However, 
should technical limitations of current tissue culture 
approaches are overcome; new data indicate that 
the presence of TILs positively correlates with patient 
survival in ovarian and colorectal cancer[95,119] and 
have a important role in pancreatic cancer[120] , thus 
prompting the enforcement of this protocol for other 
usually encountered epithelial cancers.
In the past, we have demonstrated, in GC patients, 
the functional role of TILs reactive vs different peptides 
of GC-associated antigens[121]. We have documented 
a peptide-specific T-cell response in 17 out of 20 
enrolled patients and the majority of specific TILs had 
an effective role showing a T helper 1 (Th1) cytokine 
profile with high cytotoxic activity. In other words, in 
most of GC patients, a specific type-1 T-cell response 
to GC antigens was detectable and would have the 
potential of killing the cancer cells. But, in order to get 
“in vivo” tumor cell destroying, the the quantity and 
quality of tumor-specific T cells almost certainly need 
to be enhanced by vaccination with the appropriate 
cancer antigens/peptides or by injection of the 
autologous cancer-specific T cells, previously expanded 
in vitro.
It is remarkable to note that not always the 
lymphocytic infiltrate has an anti-cancer role and often 
the TILs can promote the expansion of tumor cells. 
Recently, we have investigated the functional profile of 
HP0175-specific TILs in GC patients, infected with H. 
pylori. The TILs cells were able to produce IL-17 and 
IL-21 in response to HP0175 but showed poor cytolytic 
activity and high helper activity for monocyte MMP-2, 
MMP-9 and VEGF production. In a nutshell, these data 
suggest that HP0175 drives gastric Th17 response 
and promoting pro-inflammatory low cytotoxic TIL 
response, so providing a link between H. pylori and 
gastric cancer[122].
In addition, different studies highlight that most 
of GC TILs show a Treg profile. Recently, Shen et 
al[123] demonstrated that that CD4+ and CD8+ TILs 
were not associated with the OS of GC patients and 
that in the tumor sites, higher Tregs/CD8+ ratio was 
an independent factor for worse OS (P = 0.037). 
The 1-year, 2-year and 3-year OS rates were 90%, 
77.5% and 70% for the group with intratumoral high 
Tregs/CD8+ ratio, compared with 100%, 94.3% and 
90.5% for the group with intratumoral low ratio. So, 
intratumoral high Tregs/CTLs ratio was a prognostic 
factor for GC patients. Accordingly, an independent 
study showed that a higher Tregs/Th cell ratio is 
associated with an unfavorable prognosis and loco-
regional recurrence pattern in gastric cancer[124]. 
It can be inferred that a combination of deletion 
of Tregs and stimulation of effector T cells may be a 
successful immunotherapy to prolong survival of GC 
patients.
Dendritic cell-based vaccination
Antigen presentation by dendritic cells (DCs) is 
essential to start the cellular immune responses 
required for tumor immunotherapy[125,126] (Figure 1). 
In addition, in mouse models ex vivo generated DCs 
can provoke antigen-specific T-cell responses[127], 
supporting the use of DC-based anticancer vaccines in 
clinical studies[128].
In GC patients the number of DCs correlates 
with the clinical stage and prognosis: patients with 
abundant DCs infiltration showed a better 5-year 
survival rates than patients with smaller amount of 
DCs[129,130]. Moreover, it has been documented that 
the use of adjuvant immunotherapy enhances the 
survival in resected GC patients with small tumor DCs 
infiltration[131].
Of the 325 trials reported in ClinincalTrials. Gov 
on DC therapy, six studies involve GC patients (Table 
1)[132-134] but only three have been terminated (Table 1) 
and only two have published their results.
Kono et al[132] reported a phase-Ⅰ clinical study 
of GC patients treated with DCs pulsed with HER-2/
neuro-peptides. After the vaccination, one (out of 9 
patients HER-2/neu+) showed decreased levels of CEA 
and CA19-9 while two registered a significative cancer 
regression (> 50%). Of note, the vaccine protocol did 
not register considerable side effects.
Recently Sadanaga et al[133] published the results of 
a phase-I trial, where twelve patients, with advanced 
gastrointestinal carcinoma, were immunized with 
DC pulsed with MAGE-3 peptides without significant 
side effects. After vaccination, in four patients was 
registered the presence of peptide-specific CTL while 
in seven was observed the serum decrease of cancer 
markers. In addition, small cancer regressions were 
highlighted in three patients.
Finally, Galetto et al[135] described that memory 
T cell specific to GC antigens could be activated by 
cancer-loaded autologous DCs, isolated from blood 
mononuclear cells and activated by stimulation with 
apoptotic autologous tumor cells.
Nevertheless, the clinical application of DC vaccines 
has been limited for the the short lifespan of DCs, and 
one of the factors threatening DC survival is antigen-
specific CD8+ that acquire cytolytic activities after 
activation by DCs[136].
In recent times, Kim et al[98] ameliorated the 
efficiency of a DC vaccine with a small interfering RNA 
(siRNA) targeting phosphatase and tensin homolog 
(PTEN), that has a key role as a negative regulator in 
the signal transduction of the PI3K/AKT pathway[137].
The PTEN downregulation in DCs resulted in AKT-
dependent maturation, which generated a considerable 
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surface hyperexpression of costimulatory molecules 
and the chemokine receptor, CCR7, leading to an 
increased T cell activation in vitro and a migration to a 
draining lymph node in vivo, respectively. In addition, 
the PTEN siRNA transfected DCs (DC/siPTEN) showed 
an augmented survival and most remarkably, DC/
siPTEN generated a major number of cancer-specific Tc 
cells and a stronger anticancer response in vaccinated 
mice compared to the controls.
In short, these data suggest that manipulation of 
the PI3K/AKT pathway with the siRNA system could 
improve the efficacy of a DC-based tumor vaccine, 
such as in GC treatment.
Immunosuppressive factors, such as IL-10, secreted 
by DCs (or other regulatory cells) downregulates the 
Dcs functionality by specific surface receptors (e.g., 
IL-10R). Recent data showed that the targeting IL-10 
receptor with siRNA, can increase the effectiveness of 
DC-based vaccine, suggesting a potential clinical use of 
siRNA[138].
In addition, very interesting are the results of He 
et al[139] concerning the opportunity of increasing the 
anticancer immunity through GM-CSF gene-modified 
DCs. After GM-CSF gene modification, DCs are able to 
secrete elevated levels of GM-CSF and have a major 
propensity to be maturated. In this way, the DCs 
increase their ability of activating the proliferation of T 
cells. In addition, in vitro the dendritic cells with GM-
CSF gene modified can stimulate specific CTL to kill 
the cancer cells.
Finally, in comparison with the vaccination alone, 
DCs vaccination and the preventive removal of Tregs 
substantially enhances the activation of tumor-specific 
T-cell responses[140].
Treatments by using NK cells
The NK cells are able to arrest the metastatic 
spreading of human cancers[141] and also, the intra-
cancer infiltration of NK cells is associated with a better 
prognosis of GC patients[142]. The key function of NK 
cells in anti-tumor response gives us the possibility 
to counteract the cancer progression by manipulating 
the NK cell “arms”. However, some obstacles make 
it difficult to the therapeutic use of NK cell-based 
treatments: (1) unfinished characterization of the 
specific function of the different NK cell subpopulations; 
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(2) little knowledge of the mechanisms involved in NK 
functionality; (3) the exiguous amount of blood NK 
cells; and (4) the troubles about a massive production 
in good manufacturing practices (GMP) of NK cells[143]. 
About gastric cancer, a recent study evaluated the 
NK number in 72 patients with gastric adenocarcinoma 
and its correlation with patient survival. The conclusions 
are that patients with high concentration of NK cells 
showed a higher survival rate when compared to the 
low concentration, especially in the advanced stage[144].
Moreover, very interesting data have been obtained 
by Saito et al[145] which demonstrated that the 
frequency of apoptotic NK cells in GC patients was 
significantly higher than in normal controls. Moreover, 
their frequency was related to the GC progression. 
Fas+ NK cells were significantly more common in 
GC patients compared with normal controls and Fas 
expression was closely related to the frequency of NK 
cell apoptosis. Also, the frequency of tumor-infiltrating 
NK cell apoptosis was significantly higher than that of 
circulating NK cell apoptosis. Furthermore, apoptotic 
circulating NK cells significantly decreased after 
surgery compared to before surgery.
Finally, Voskens et al[146] showed that numerous 
cytotoxic NK cells can be obtained from cancer 
patients co-culturing autologous PBMC with K562 
cells. Of note, the ex vivo development increased the 
cytotoxic activity of NK cells vs the autologous derived, 
suggesting a future clinical application, as cell-based 
immunotherapy, for autologous expanded NK cells (as 
alone as and in association with specific monoclonal 
antibodies).
Very interesting are the recent results about 
lupeol, a triterpene that has curative action vs various 
diseases. Recently, Wu et al[147] showed that lupeol is 
able to favor the proliferation of NK cells, increasing 
also their killing action vs the GC cells. Moreover, lupeol 
inhibit the proliferation of different GC cell lines. These 
data suggest that lupeol could serve as a potential 
agent against gastric cancer alone or with adoptive 
transfer of NK cells.
FUTURE DIRECTIONS
We have used this review to provide a panoramic 
view about the current immunotherapeutic anti-
GC approaches, some of which have been used 
in clinical trials with fairly good results about the 
tumor regression and patient survival. But, the role 
of immunotherapy for gastric cancer continues to 
evolve. As the current development suggests, gastric 
cancer therapy has suffered from a relative lack 
of gastric-specific biological exploration. The most 
common developmental path to date has been limited 
to the study of immune-based therapies that have 
demonstrated efficacy in other somewhat similar 
diseases, and then have been tested in gastric cancer.
Moreover, an additional great challenge in the field 
is to develop randomized clinical trials validating the 
medical benefits to justify the logistics and especially 
the costs of these personalized cell treatments.
Usually the clinical trials enroll patients with advanced 
GC, this factor could determine an unfavorable result, 
because the anti-cancer battle of current immune 
response is already a lot compromised. For this purpose, 
it would be strategic to recruit early-stage GC patients, 
that being in the early stages of tumor development, 
may better react to the immunotherapy strategies.
Finally, to set up successful anti-GC immunotherapy 
approaches, it is necessary to understand the “fine” 
immune escape mechanisms, adopted by the cells of 
gastric cancer.
Past and recent studies have supplied new insights 
about the thick crosstalk between tumor and immune 
cells. Comprehending this operative dialogue and the 
hierarchic grade of the various cancer-immune evasion 
mechanisms at distinct steps of neoplastic evolution, 
will guide the development of innovative curative 
strategies aiming to demolish the “tumor fortress”.
So, it will be remarkable to evaluate the pathways 
of the various components that modulate the growth 
and mobility of Tregs, MDSCs and tolerogenic DCs 
within cancer-draining lymph nodes and the cancer 
surroundings.
Another important target for the future anti-GC 
immunotherapy treatment could be the immune 
checkpoints[148] that are inhibitory pathways hardwired 
into the immune system. The immune checkpoints 
play critical roles for physiological homeostasis because 
they are essential for maintaining self-tolerance and 
modulating the duration and amplitude of physiological 
immune responses in order to minimize collateral 
tissue damage. But, these checkpoints may also allow 
immune escape in cancer.
Checkpoint pathways are regulated by ligand/
receptor interactions. For example, programmed 
death-1 receptor (PD-1) and CTL-associated antigen 
4 (CTLA-4) are inhibitory molecules whose presence 
on lymphocytes signifies a blunted immune response. 
PD-1 negatively regulates T cell responses and 
downregulation and eventually apoptosis is initiated 
following binding of a PD-1 ligand with PD-1. PD-1 
ligands, PD-L1 or PD-L2, are frequently expressed 
on tumor cells and can thus thwart the immune 
response. One approach to overcome this inhibition 
of the immune response has been to target immune 
checkpoints with blocking moAb. For example, PD-1 
moAb binds to the PD-1 receptors on T cells and 
inhibits their binding to the ligands on tumor cells 
thus preventing the tumors from down regulating the 
cytotoxic lymphocyte response. This approach has 
been successful clinically in advanced melanoma[149,150]. 
and phase Ⅰ clinical trials of anti-PD-L1 moAb are 
under investigation for gastric cancer[148].
It is realistic to declare that, in the future effective 
anti-GC immunotherapy strategies must include 
combined approaches, which should use both systemic 
radio/chemotherapy and transplantation, to diminish 
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the burden or to remove immune suppressive cells, 
and tailored immunotherapies customized to each 
single patient.
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